Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV brincidofovir versus IV cidofovir for adenovirus viremia after allogeneic stem cell transplant
NL-OMON61717Phase 3Not yet recruiting
- Sponsor
- SymBio Pharmaceuticals
- Start
- Apr 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in adenoviral infection comparing IV brincidofovir with IV cidofovir (2 arms). Primary endpoint: Proportion of subjects with AdV virological success. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
brincidofovircidofovir
03
Conditions
adenoviral infection
Beyond the preview
Go deeper on NL-OMON61717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61717.